Puma Biotechnology | PBYI - Operating Profit


Puma Biotechnology reported $22.08M in Operating Profit for its fiscal quarter ending in September of 2024.





Operating Profit Change Date
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
Amgen USD 4.61B 777M Jun/2026
Biogen USD -243.8M 758.1M Jun/2026
BioMarin Pharmaceutical USD 105.6M 24.04M Jun/2026
Daiichi Sankyo JPY 85.1B 4.44B Jun/2026
Exelixis USD 248.41M 2.93M Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Glaxosmithkline GBP 2.29B 3.08M Mar/2026
Incyte USD 700.4M 376.22M Jun/2026
MacroGenics USD -33.44M 21.34M Mar/2026
Moderna USD -815M 573M Jun/2026
Novartis USD 4.75B 515M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
Takeda JPY 201.42B 215.04B Jun/2026
TG Therapeutics USD 21.67M 13.12M Jun/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026